Viaderma Graham Number
Graham Number of Viaderma (VDRM) as of Nov 12, 2026.
Get this data via API
Financial Data API
Graham Number
0.00USD
Last updated:
Graham Number of Viaderma is 2023 0.00 USD. Graham Number of Viaderma was 2022 - USD. It decreases by % lower compared to the previous year.
The Viaderma Graham Number history
| YEAR | Graham Number | YoY |
|---|---|---|
| 0.00USD | — |
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Viaderma Stock analysis
What does Viaderma do? ViaDerma, Inc. generates revenue through the manufacturing and sale of pharmaceutical products, primarily its lead product Vitastem, a topical antibiotic brand. The company sells Vitastem directly to local medical practitioners and patients in clinics within the Los Angeles area, focusing on treating various skin conditions. Additionally, ViaDerma licenses its proprietary transdermal delivery technology, which enables rapid transfer of active ingredients through the skin for immediate localized therapy. The company also develops products in anti-aging skin care, pain management, hair-loss, and toenail fungus, though these are not yet commercialized.
ViaDerma, Inc. operates through its subsidiary ViaDerma, II Inc., which supports the development and commercialization of its product portfolio. The company's revenue streams include direct sales of Vitastem to healthcare providers and patients, as well as licensing fees from its transdermal technology. The primary market segments are medical practitioners and patients seeking treatments for skin ailments in the Los Angeles region, with future growth potential in emerging product categories like anti-aging and hair-loss solutions.
The company's business model centers on proprietary technology that differentiates its products, allowing for faster and more effective treatment delivery. Vitastem is the cornerstone of its current revenue, while the transdermal technology serves as a complementary asset for both current and future product lines. This approach enables ViaDerma to target specific medical needs with localized solutions, primarily in the Los Angeles market, while expanding into new therapeutic areas through its pipeline. Viaderma is one of the most popular companies on Eulerpool.
Frequently Asked Questions about Viaderma stock
On Eulerpool you can find the complete historical development of Graham Number Viaderma since 2006 – with annual values, charts, and detailed analysis.
The Graham Number estimates the maximum fair price for a stock based on EPS and book value per share, following Benjamin Graham's value investing principles.
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Quality — Viaderma
All Key Metrics — Viaderma
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth